Citius Oncology (CTOR) Non-Current Deferred Tax Liability (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $2.8 million in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 24.88% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 24.88% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, up 61.17% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $2.8 million, down from $3.0 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for CTOR reached as high as $3.0 million in Q4 2025 and fell as low as $1.2 million in Q3 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $2.3 million across 4 years, with a median of $2.4 million in 2025.
• Across the five-year window, Non-Current Deferred Tax Liability surged 61.17% in 2025 and climbed 24.88% in 2026, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $1.2 million in 2023, then jumped by 72.94% to $2.0 million in 2024, then jumped by 53.05% to $3.0 million in 2025, then slipped by 7.58% to $2.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $2.8 million in Q1 2026, $3.0 million in Q4 2025, and $2.8 million in Q3 2025.